NMT completes enrollment in UK
This article was originally published in The Gray Sheet
Executive Summary
The 60-patient, multi-center BEST study (BioSTAR Evaluation STudy) has finished enrolling patients, the firm announces Nov. 29. The trial, which is designed to support a CE mark, is evaluating the BioStar bioabsorbable collagen matrix technology's ability to close the patent foramen ovale, which could treat migraine headaches, recurrent stroke and transient ischemic attack (1"The Gray Sheet" March 27, 2005, p. 29). The firm expects approval by the end of 2006...